CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.
CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
抗原逃逸可削弱嵌合抗原受体(CAR)或T细胞受体(TCR)工程化T细胞的疗效。靶向多种抗原可有效限制抗原逃逸,而将CAR与TCR介导的靶向相结合可显著拓宽可靶向抗原的范围。
在此,我们探讨了能否通过联合TCR和CAR工程在T细胞上赋予双抗原特异性,以防止多发性骨髓瘤(MM)的抗原逃逸。我们报道了生成经转导表达转基因TCR的CD8 T细胞,该TCR靶向HLA-B 07:02背景下源自转录辅激活因子BOB1的肽,同时表达靶向BCMA的CAR。这些T细胞被称为TRaCR T细胞,能够有效识别对BOB1 TCR或BCMA CAR-T 细胞耐药的靶细胞,说明其具有普遍的双特异性。
然而,在两种抗原均存在时,靶细胞识别优先由CAR介导,从而损害TCR介导的靶细胞识别。重要的是,在异质性MM体内模型中,这导致缺乏BCMA表达的肿瘤细胞获得生存优势。
总之,我们证明了TRaCR T细胞具有普遍的双特异性,但建议在将TRaCR T细胞作为靶向异质性肿瘤策略时需谨慎。
Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens.
Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM).
We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B 07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition.
Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM.
In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。